Medical cannabis shows efficacy for MS spasticity (oral cannabis extract), probable efficacy for pain, but probable ineffectiveness for tremor and unclear evidence for epilepsy and other neurological diseases.
AAN guideline based on systematic review of k=34 studies (8 Class I) on medical cannabis in MS. Spasticity: oral cannabis extract (OCE) effective, nabiximols and THC probably effective for patient-centered measures. Central pain/painful spasms: OCE effective, THC and nabiximols probably effective. Bladder dysfunction: nabiximols probably effective (reduction in bladder voids/day), THC and OCE probably ineffective. Tremor: THC and OCE probably ineffective. Risk of serious psychopathological adverse effects <1%.
The highest of four GRADE levels, the effect estimate is very reliable.
The impediment to action advances action.